Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test
07:00am, Monday, 06'th Jan 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Es
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
08:50am, Monday, 23'rd Dec 2024
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
07:00am, Monday, 23'rd Dec 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 19'th Dec 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employee
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns
08:01am, Tuesday, 17'th Dec 2024
Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade
10:57am, Monday, 16'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, t
Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside
08:50am, Thursday, 28'th Nov 2024
These five small cap stocks have strong growth potential for 2025. These are: TALK, RYAM, CSTL, PBAM, RSSS.
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
07:00am, Wednesday, 20'th Nov 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024,
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why
09:56am, Friday, 08'th Nov 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Rec
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP24--Castle will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the ASDP 61st Annual Mee
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
01:00pm, Thursday, 07'th Nov 2024
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
07:33pm, Monday, 04'th Nov 2024
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Presi
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates
06:56pm, Monday, 04'th Nov 2024
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
10:16am, Friday, 01'st Nov 2024
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esoph
